HCPCS Code J0185: Injection, aprepitant, 1 mg billing guide

Key Takeaways

HCPCS Code J0185 describes Injection, aprepitant, 1 mg (Cinvanti), an NK-1 receptor antagonist for chemotherapy-induced nausea and vomiting

One billable unit equals 1 mg: a 130 mg Cinvanti vial generates exactly 130 units of J0185 per claim

Always append either JW or JZ modifier to J0185 claims to report drug wastage or confirm none occurred

Pabau’s claims management software tracks J-code billing units and modifier requirements to reduce oncology claim denials

HCPCS code J0185 (Injection, aprepitant, 1 mg) covers Cinvanti, an NK-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). This guide covers billing unit calculations, modifier requirements, NDC crosswalk, CPT pairings, payer coverage, and CMS-1500 claim instructions for J0185.

HCPCS code J0185: Definition and clinical description

HCPCS code J0185 is the Level II code for Injection, aprepitant, 1 mg. Aprepitant is a neurokinin-1 (NK-1) receptor antagonist that blocks substance P signaling in the central nervous system to prevent acute chemotherapy-induced nausea and vomiting (CINV). The injectable formulation, branded as Cinvanti by Heron Therapeutics, is administered intravenously as a single dose prior to chemotherapy.

The drug’s single-dose vial contains 130 mg, but J0185 bills at 1 mg per unit — one missed decimal point creates a 130× overbilling error or a 130× underpayment.

Billing units and unit calculation for J0185

Getting the unit count right is the most error-prone step in J0185 billing. CMS defines the billable unit as 1 mg of aprepitant.

Cinvanti is supplied as a 130 mg/18 mL injectable emulsion single-dose vial (NDC 47426-0201-xx), as confirmed by OHSU Health Services and Moda Health Plan payer policies citing the Cinvanti package insert. Because the vial is single-dose, any unused portion after the patient dose is discarded.

The JW modifier captures that discarded volume; JZ confirms nothing was wasted. Both scenarios require billing units to reflect the full vial contents across the two line items, not just the administered dose alone.

For IV therapy EMR documentation, the administered dose and any discarded amount should be recorded separately in the clinical note so the modifier assignment is defensible at audit. A single line of documentation (“130 mg administered, 0 mg discarded, JZ modifier applied”) is sufficient for most payer audits. Practices that also bill for supplies for self-administered injections should keep similar per-dose records to support those claims.

J0185 NDC crosswalk

Many commercial payers and Medicaid programs require the National Drug Code (NDC) to appear on J0185 claims alongside the HCPCS code. Omitting the NDC is a common denial trigger, particularly for buy-and-bill oncology drugs.

• NDC for Cinvanti 130 mg/18 mL single-dose vial: 47426-0201-xx (the final two digits represent the package size)
• NDC format on claims: 11-digit format (5-4-2), no hyphens: 47426020100 or 47426020101 depending on package
• NDC quantity unit: report in millilitres (ML); 18 mL for a full 130 mg vial
• NDC qualifier on CMS-1500: use qualifier N4 in the shaded portion of Box 24A
• On UB-04 (facility claims): NDC appears in Form Locator 43, Value Code A1/A2 depending on payer

Some carriers list NDC reporting for J0185 as “carrier judgment,” meaning it is optional at their discretion. However, submitting the NDC proactively on every J0185 claim prevents processing delays and reduces the risk of requests for additional information. Verify NDC requirements with each payer before the first claim submission.

JW and JZ modifier guidance for J0185

CMS modifier policy requires practices to document and report drug wastage on single-dose vial J-codes. For J0185, this means one of two modifiers must appear on every claim line.

For Cinvanti 130 mg: if the full vial is administered to one patient, report 130 units of J0185 with the JZ modifier on one claim line. If only 100 mg is administered, report 100 units of J0185 (no modifier or JZ if practice confirms no waste) on line one, then 30 units of J0185-JW on line two for the discarded 30 mg.

The JZ modifier was introduced by CMS to reduce administrative burden on practices that administer the full vial with no wastage. The Heron Therapeutics Cinvanti Coding Reference Guide confirms J0185 may be used for Cinvanti administered on or after January 1, 2019. Effective date matters: claims for earlier dates of service require verification against the legacy HCPCS code in effect at that time.

Practices managing drug inventory management workflows should record lot numbers, vial dates, and administered vs discarded quantities at the point of care to support modifier assignment at billing time. Teams handling other injectable oncology drugs can also reference the HCPCS code J9299 billing guide for nivolumab for parallel modifier and unit-calculation workflows.

Automate J-code billing across your oncology workflows

Pabau's claims management tools help oncology and infusion practices track HCPCS billing units, assign modifiers accurately, and submit cleaner claims with fewer denials.

Book a demo

CPT codes paired with J0185

J0185 does not stand alone on a claim. Infusion administration requires a separate CPT administration code on the same claim. The Heron Therapeutics sample CMS-1500 Claim Form confirms two CPT codes commonly appear alongside J0185:

• CPT 96367 (Intravenous infusion, for therapy/prophylaxis/diagnosis; additional sequential infusion of a new drug or substance, up to 1 hour): used when aprepitant is administered as an additional sequential infusion during a chemotherapy session already in progress
• CPT 96375 (Therapeutic, prophylactic, or diagnostic injection; each additional sequential intravenous push of a new drug or substance): used when aprepitant is given as an IV push following an initial infusion service

Which CPT code applies depends on the route and sequence of administration. If aprepitant is the initial drug infused at the visit, the primary infusion code (96365 or 96413 for chemotherapy) may be more appropriate as the lead code, with 96367 or 96375 used for any subsequent drugs. Review NCCI (National Correct Coding Initiative) edits before finalising the pairing, as bundling rules can affect payment when multiple infusion codes appear on the same claim.

For practices using claims management software, automating the J0185 plus CPT pairing as a billing template reduces manual errors and ensures the modifier and NDC fields populate consistently across all aprepitant administrations. For a related infusion administration code, see the CPT code 96360 IV hydration billing guide.

Medicare reimbursement and payer coverage for J0185

J0185 falls under Medicare Part B as a drug administered in a physician office or hospital outpatient department. Reimbursement is calculated using the Average Sales Price (ASP) methodology, not the Wholesale Acquisition Cost (WAC) or Average Wholesale Price (AWP).

• ASP-based reimbursement: Medicare pays ASP + 6% for most Part B drugs; verify the current quarter’s payment rate in the CMS Physician Fee Schedule lookup tool before billing. For practices also billing subsequent hospital visits during the same oncology episode, review the CPT code 99232 subsequent hospital inpatient care billing guide.
• WAC pricing: applies when ASP data is unavailable; WAC + 3% is the fallback under Medicare Part B
• AWP pricing: used by some commercial payers; not the Medicare standard but relevant for private insurance contracts
• Buy-and-bill model: most oncology practices purchase Cinvanti directly and bill through the medical benefit (Part B), not the pharmacy benefit; confirm coverage routing with each payer

Prior authorization requirements for J0185 vary significantly by payer. OHSU Health Services, Moda Health Plan, and Prime Therapeutics have published medical necessity criteria for Cinvanti that require the drug to be used for CINV prophylaxis in patients receiving moderately or highly emetogenic chemotherapy. UnitedHealthcare Community Plan lists J0185 alongside related antiemetic J-codes including J1453 (fosaprepitant), J1434, J1454 (fosnetupitant/palonosetron), and J1456. Check each payer’s current LCD (Local Coverage Determination) or plan-specific policy before administration to avoid prior authorization denials.

Understanding IV therapy clinic best practices for documentation supports prior authorization requests: clinical notes must confirm the chemotherapy regimen’s emetogenic risk classification and the patient’s previous antiemetic treatment history. Oncology coders should also be familiar with diagnosis codes such as ICD-10 code C18.1 (malignant neoplasm of appendix) and ICD-10 code C20 (malignant neoplasm of rectum) that frequently appear alongside antiemetic claims.

CMS-1500 claim form instructions for J0185

Completing the CMS-1500 correctly for J0185 prevents the most common front-end rejections. The Heron Therapeutics sample claim form provides the box-by-box reference for Cinvanti billing.

• Box 21: ICD-10-CM diagnosis codes for the patient’s cancer type and CINV risk indication (e.g. C34.10 for primary malignant neoplasm of bronchus/lung)
• Box 24B: Place of service code (11 = physician office, 22 = hospital outpatient)
• Box 24D: HCPCS code J0185 on line 1; CPT administration code (96367 or 96375) on line 2
• Box 24F: Dollar amount for each line (ASP-based for J0185; facility fee or RVU-based for CPT)
• Box 24G: Units (number of billable mg administered; 130 for a full Cinvanti vial)
• Box 24A (shaded line): NDC in 11-digit format with N4 qualifier and quantity in ML
• Box 24D (second J0185 line, if applicable): Discarded units with JW modifier

For facility claims on the UB-04, J0185 appears in Revenue Code 636 (pharmacy) alongside the NDC in Form Locator 43. The billing structure mirrors CMS-1500 logic but uses revenue codes instead of place-of-service codes.

Practices handling IV therapy intake documentation should ensure the patient’s chemotherapy order, administered drug, dose, route, and time of administration are captured in the clinical record before claim submission. This documentation forms the audit trail for all J0185 line items. Coders working across multiple unclassified biologics may also want to bookmark the HCPCS code J3590 unclassified biologics billing guide for situations where a specific J-code has not yet been assigned.

Related HCPCS codes: NK-1 antagonist alternatives

J0185 is one of several HCPCS codes covering injectable NK-1 and combination antiemetics used in CINV prophylaxis. Knowing the related codes reduces crosswalk errors when a different drug is substituted mid-treatment.

Aprepitant (J0185) and fosaprepitant (J1453/J1434/J1456) target the same receptor but differ in formulation: aprepitant is a direct IV emulsion, while fosaprepitant is a prodrug converted to aprepitant after administration. The HCPCS code follows the drug dispensed, not the mechanism of action, so substituting one for the other requires a code switch on the claim. For mobile IV therapy billing scenarios where the drug dispensed may vary by availability, having all four fosaprepitant codes pre-loaded in the billing system prevents last-minute code errors. Practices billing other specialty injectables can review the HCPCS code J9217 leuprolide acetate billing guide for a parallel example of unit-based J-code billing.

The CMS HCPCS overview provides the official annual HCPCS Level II code update files, which should be reviewed each October 1 when new codes take effect. Related J-code examples include the HCPCS code J1306 inclisiran 1 mg billing guide and the HCPCS code J1559 Hizentra billing guide, both of which follow similar per-milligram unit conventions.

Common denial reasons and appeal strategies for J0185

J0185 claims deny for a narrow set of reasons, most preventable with front-end billing controls.

• Missing or incorrect NDC: Submit NDC 47426-0201-xx with N4 qualifier and ML quantity on every claim. Set this as a required field in the billing template for J0185.
• No JW or JZ modifier: CMS and most commercial payers expect one of the two modifiers on every J0185 line item for single-dose vials. Missing modifiers trigger claim suspension or denial.
• Units billed as “1” instead of “130”: The unit field must reflect milligrams administered. Defaulting to “1” is a near-universal data-entry error for first-time J-code billers.
• Missing prior authorization: Payers requiring PA for Cinvanti will deny on first submission. Verify PA status before administration, not at billing time.
• Incorrect CPT pairing: Using 96365 (initial infusion) when 96367 (additional sequential) is correct inflates the claim and may trigger NCCI edit denials.
• Stale ASP rate on appeal: When appealing a J0185 underpayment, include the current quarter’s CMS ASP + 6% calculation and the relevant CMS drug pricing file citation.

Practices setting up their who can administer IV therapy policies should also establish a pre-submission checklist that flags J0185 claims missing the NDC, modifier, or PA reference number before the claim leaves the practice. For additional insight into growing the patient base that benefits from these services, see how to get more patients: 7 strategies that fill schedules.

Conclusion

J0185 billing comes down to three numbers: 130 units per vial, one of two modifiers per claim, and the current quarter’s ASP rate. Getting any one wrong produces either a denial or a compliance exposure.

Pabau’s claims management tools help infusion and oncology practices pre-populate J-code billing templates with the correct unit calculations, modifier logic, and NDC fields, reducing manual entry errors before submission.

Practices managing chronic infusion patients may also benefit from reviewing CPT code 99490 chronic care management billing for complementary reimbursement opportunities. To see how Pabau handles J-code claim workflows end to end, book a demo.

Continue your research

Need an IV therapy EMR that tracks administered drug volumes? Best EMR for IV therapy reviews the top platforms for infusion-heavy practices managing J-code billing.

Want a pre-built intake form for IV drug administration? IV therapy intake form covers the documentation fields that support modifier assignment and audit defence.

Building an oncology or infusion clinic from scratch? How to open an IV therapy clinic walks through licensure, equipment, and billing setup requirements.

Frequently asked questions